If you are fortunate enough to have $7,000 to invest into the share market, then you will undoubtedly want to put these funds in the highest quality Australian stocks you can find.
But which stocks tick this box?
Let's take a look at three stocks that brokers recommend that are so high quality that they could be classed as no-brainer buys.
Here's what you need to know about them:
Image source: Getty Images
Goodman Group (ASX: GMG)
Goodman Group could be a no-brainer Australian stock to buy. It has become a standout performer in the property sector by focusing on high-quality industrial real estate. Its portfolio includes logistics warehouses, distribution centres, and data centres. These are assets that sit at the heart of modern supply chains and the digital economy.
What sets Goodman apart is its exposure to structural growth drivers like e-commerce and cloud computing. As retailers and tech giants continue to expand, demand for Goodman's properties has surged. The company also has a large development pipeline, which should support growth for many years to come.
The team at Citi is bullish on Goodman Group. So much so, this week it put a buy rating and $40.00 price target on its shares.
REA Group Ltd (ASX: REA)
Another Australian stock to consider for the $7,000 is REA Group. It is the dominant player in Australia's online property advertising market, operating realestate.com.au and several international property platforms. This dominance gives it pricing power and a natural advantage over competitors.
And even though property markets can go through cycles, REA has consistently grown revenue and earnings by offering new services and leveraging its brand strength.
For investors looking for exposure to the long-term strength of Australia's housing market, REA is hard to beat.
Morgan Stanley is bullish on the company's outlook. It has an overweight rating and $300.00 price target on its shares.
ResMed Inc. (ASX: RMD)
A final no-brainer buy could be ResMed. It is a leader in sleep disorder treatment devices and masks, as well as connected digital health platforms.
With over a billion people worldwide estimated to be affected by sleep and respiratory disorders, ResMed has a huge addressable market. Especially given that the majority of sufferers are undiagnosed and unaware of their conditions.
But with awareness growing thanks to educational initiatives and even smart watches, ResMed appears well-placed to continue its solid growth over the next decade and beyond.
As a result, for investors seeking an innovative business with global scale and strong recurring revenue, ResMed could be a great choice.
Macquarie certainly thinks it would be a top pick for investors. It has an outperform rating and $48.60 price target on its shares.
